A b s t r a c t
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma, is a malignant neoplasm composed of immature hematopoietic cells thought to be precursors of plasmacytoid dendritic cells. [1] [2] [3] [4] [5] The most frequent manifestation is that of an asymptomatic patient with a skin lesion. 2, 3, 6, 7 Myeloid leukemia cutis (LC) is an important consideration in the differential diagnosis of BPDCN. Myeloid LC and BPDCN are associated with an aggressive clinical course; however, it is important to distinguish these entities because evolving literature suggests optimal therapy for these relatively uncommon hematopoietic malignancies may be different, including aggressive treatment and consideration for early bone marrow or stem cell transplantation in BPDCN. [8] [9] [10] Clinically and histologically, myeloid LC and BPDCN may be difficult to distinguish. 2, [11] [12] [13] [14] Clinically, lesions of both entities are characterized by single or multiple papules, nodules, or plaques that may range from violaceous to redbrown. 7, 11, 15 BPDCN often has its initial manifestation in the skin, and myeloid LC may also precede clinically detectable systemic leukemia (so-called aleukemic leukemia cutis). 16, 17 Histologically, myeloid LC ❚Image 1❚ and BPDCN ❚Image 2❚ are characterized by a diffuse, interstitial infiltrate of blastic cells involving the dermis, sometimes extending into the subcutis. Occasional infiltrates are more sparse and distributed in a periadnexal or perivascular pattern. 7, 18 Lesional cells in both entities are medium to large with open chromatin, irregular nuclear membranes, prominent nucleoli, and increased mitotic activity. 7, 19, 20 To reliably distinguish myeloid LC from BPDCN in paraffin-embedded tissue sections, use of immunohistochemical Upon completion of this activity you will be able to:
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of BPDCN diagnosed between 1996 and 2007 that had paraffin-embedded materials available for this study. An additional 2 cases of BPDCN with available materials were provided by one of us (K.R., University of New Mexico, Albuquerque). All of the cases of myeloid LC and one of the cases from the University of New Mexico were previously reported. 13, 27 Corresponding bone marrow aspirate, cytogenetic and/or molecular genetic data, and flow cytometric data were obtained when available, and the diagnoses were classified using the published 2008 World Health Organization (WHO) criteria. 3 Other clinical data obtained about the patients included age, sex, location of the biopsy, and clinical appearance of the lesions. This study was approved by the Stanford University Institutional Review Board.
Immunohistochemical Studies
H&E-stained sections and immunohistochemical studies performed at the time of diagnosis were reviewed to confirm staining is of paramount importance. However, this may be problematic because both entities share expression of many antigens. 2, 14, [21] [22] [23] [24] [25] [26] Despite their similarities, emerging research has demonstrated that several key immunohistochemical stains may be able to differentiate myeloid LC from BPDCN. 2 Given this background, we sought to identify immunohistochemical profiles that would discriminate myeloid LC and BPDCN in paraffin-embedded skin biopsy specimens. In particular, we included 12 cases of myeloperoxidase (MPO)-negative myeloid LC because these cases are particularly challenging to distinguish from BPDCN.
Materials and Methods

Case Selection
The pathology database of Stanford University Medical Center, Stanford, CA, was searched for cases of myeloid LC and BPDCN. We found 23 cases of myeloid LC and 10 cases the original findings. We also reviewed corresponding flow cytometric and cytogenetic/molecular data, as applicable. Additional immunohistochemical studies were performed on formalin-fixed, paraffin-embedded tissue using a Ventana Benchmark semiautomated stainer (Ventana Medical Systems, Tucson, AZ), an automated DAKO polymer-based detection system (DAKO, Carpinteria, CA), or a manual protocol. Manual staining was performed using an ImmPRESS reagent antimouse immunoglobulin or antirabbit IgG kit manufactured by Vector Laboratories, Burlingame, CA. Staining was performed on paraffin-embedded tissue sections prepared using the Trilogy kit by Cell Marque, Rocklin, CA (combined deparaffinization and heat-induced antigen retrieval procedure). Primary antibodies directed against CD4, CD11c, CD14, CD33, CD56, CD123, MPO, and Tcl-1 were used. The antibody sources, dilutions, epitope retrieval procedures used before incubation with the primary antibody, automated stainer used, and staining patterns are summarized in ❚Table 1❚. Staining for all markers was defined as follows: positive, moderate to intense staining of at least 5% of lesional cells; or negative, faint staining of fewer than 5% of lesional cells to no staining of lesional cells. 28 Diffuse faint staining was not seen in any of the cases. Positive and negative control samples reacted appropriately for all antibodies.
Results
Clinical data are itemized for the 23 myeloid LC and 12 BPDCN cases in ❚Table 2❚. Among patients with myeloid LC, there were 14 males and 9 females with an average age of 48 years (range, 22 days to 90 years). Among patients with BPDCN, there was a male predominance (10 of 12) and an average age of 59 years (range, 11-83 years). 
D E F G H D-H,
Immunohistochemical analysis reveals that the cells are negative for myeloperoxidase (MPO; D, ×600) but express CD4 (E, ×600), CD56 (F, ×600), CD123 (G, ×600), and Tcl-1 (H, ×600), which shows nuclear and cytoplasmic positivity in this case. CD123 and Tcl-1 are markers previously shown to have specificity for BPDCN, in the appropriate immunohistochemical context. These markers have generally been studied in limited numbers of myeloid LC cases. 2, 11, 38 Small studies showed that as many as 45% of myeloid LC The results of immunohistochemical stains are summarized in ❚Table 3❚ and itemized in ❚Table 4❚. Antigens most useful for distinguishing between myeloid LC and BPDCN included MPO, CD4, CD56, CD123, and Tcl-1. Antigens that did not prove useful included CD11c, CD14, and CD33. Only 1 myeloid LC case expressed both CD4 and CD56, and this case was negative for CD123 and Tcl-1. It is interesting that 2 cases of myeloid LC expressed Tcl-1 and CD123; however, these cases expressed neither CD4 nor CD56. Furthermore, these cases had bone marrow involvement and were diagnosed as acute monocytic leukemia and acute myeloid leukemia with MLL gene rearrangement (11q23), respectively.
Discussion
Differentiating myeloid LC and BPDCN may be particularly challenging on morphologic and clinical grounds alone. In addition, these distinct entities share expression of many immunohistochemical markers. In fact, these entities are both classified broadly under the heading of "acute myeloid leukemia and related precursor neoplasms" in the 2008 WHO system; however, there is some evidence to suggest that differentiating these entities may affect therapeutic decisions and therefore have potential treatment implications. 8, 9 We sought to determine if a panel of immunohistochemical markers could be used to separate myeloid LC from BPDCN and identified an immunohistochemical panel including MPO, CD4, CD56, CD123, and Tcl-1 that is useful in distinguishing these entities. First, MPO positivity excludes the diagnosis of BPDCN by definition. 3, 29 Unfortunately, many cases of myeloid LC that manifest in the skin do not express this marker (only 30% of our cases were MPO+).
The vast majority of cases of BPDCN express CD4 and CD56, as evident by this entity's former name: CD4+/CD56+ hematodermic neoplasm. The new 2008 WHO criteria for BPDCN are a bit vague regarding the criteria necessary to make the diagnosis of BPDCN in CD4-or CD56-cases. Cases of BPDCN lacking expression of either CD4 or CD56 have been reported in the literature; however, these cases are rare. [30] [31] [32] According to published literature, CD56 expression in myeloid leukemias ranges from 18% to 71% and CD4 expression rates are as high as 82%, with higher rates of both markers reported in monocytic leukemias. 14, 15, 26, [33] [34] [35] [36] [37] [38] Comparison with some of these older studies, however, is limited because most of the antigen expression was studied using flow cytometry or frozen sections. In our study, 52% of myeloid LC cases expressed CD56. CD4 expression was much less common, seen in only 9% of cases. Only 1 myeloid LC case expressed both CD4 and CD56, and this case was negative for CD123 and Tcl-1. In addition, this case had bone marrow involvement demonstrating an acute myeloid leukemia with myelodysplasia-related changes. -10  ---+  -11  --+  --12  -+  -+  -13  +  -+  --14  +  ----15  ---+  +  16  +  ----17  +  ----18  +  ----19  -----20  +  -+  --21  --+  --22  +  -+  --23  --+  --BPDCN  1  -+  +  -+ especially since we have shown that blasts may vary antigen expression between the bone marrow/peripheral blood and the skin. 13 In fact, cytogenetic studies have shown that proliferations of plasmacytoid dendritic cells and the underlying myeloid neoplasms are very closely related, perhaps representing different expressions of the same neoplastic precursor. 12, 51 This theory is in harmony with reports of myeloid neoplasms arising in patients with BPDCN, and authors have discussed the plasticity between these related but distinct neoplasms. 47, [51] [52] [53] [54] [55] [56] While a definitive diagnosis could be reached in all of our 35 total cases, it is conceivable that some cases encountered in practice may have ambiguous phenotypes intermediate between myeloid LC and BPDCN. In cases with bone marrow, peripheral blood, or lymph node involvement, alternative modalities such as flow cytometry and molecular methods may augment histologic examination and immunohistochemical findings to reach a definitive diagnosis. In persistently ambiguous cases, we agree with the 2008 WHO recommendation that such neoplasms be classified as "acute leukemia of ambiguous lineage." As new immunohistochemical markers emerge, criteria necessary for a diagnosis of BPDCN may become more refined. 51, 55, [57] [58] [59] Myeloid LC and BPDCN may be readily distinguished in cases in which MPO is positive. MPO-cases of myeloid LC, however, could be mistaken for BPDCN and vice versa. In these cases, a more thorough panel of immunohistochemical stains including CD4, CD56, CD123, and Tcl-1 will lead to the correct diagnosis in the majority of cases. Cases positive for at least 3 of these markers (including CD4 and CD56) are best diagnosed as BPDCN, while cases expressing none of these markers or only CD56 are more likely to represent myeloid LC. If the panel of markers yields ambiguous results (for example, CD56 and Tcl-1 are positive while CD4 and CD123 are not), the best diagnosis may be acute leukemia of ambiguous lineage.
cases may express CD123; however, more recently, a larger cohort of LC cases showed much less frequent expression of CD123 (8.7%). 14 Tcl-1 expression in myeloid LC is less common than CD123, staining 7% to 17% of cases. 2, 38, 39 We confirmed that both markers may be expressed in myeloid LC, with CD123 expression being more common than Tcl-1. Only 2 cases of myeloid LC expressed Tcl-1 and CD123, and these cases were negative for CD4 and CD56. While our case series is limited, all of our BPDCN cases expressed at least 3 of 4 "BPDCN markers," ie, CD4, CD56, CD123, and Tcl-1, whereas our LC cases expressed at most 2 of these markers. These results are somewhat biased because we have required the expression of CD4 and CD56 to make a diagnosis of BPDCN; however, every BPDCN case expressed either CD123 or Tcl-1, if not both.
Somewhat surprisingly, CD33 was not helpful, being positive in 92% of BPDCN and 78% of myeloid LC cases. The rates of CD33 expression by BPDCN have varied widely among studies, ranging from as low as 0% to as high as 90%. 1, 6, 7, 27, [40] [41] [42] Garnache-Ottou et al 41 convincingly showed that tumors phenotypically and functionally classified as BPDCN expressed varying amounts of CD33. CD33 expression has not been extensively studied in BPDCN in paraffinembedded tissues because its application is only recently described. 43 Rather, flow cytometric methods or studies using frozen sections represent the majority of data concerning CD33 expression in BPDCN. The fact that a high percentage of cutaneous BPDCN cases express CD33 using immunohistochemical methods is important as laboratories increasingly use CD33 for the diagnosis of myeloid neoplasms in paraffinembedded tissue.
CD11c is a marker usually expressed in myeloid dendritic cells with recently described applications in paraffinembedded tissue. It has not been shown to be expressed in cases of BPDCN using flow cytometry or frozen section antigen expression analysis. 1, 40, 44 Likewise, CD14 is another marker not expressed in BPDCN and is used in the diagnosis of myeloid and monocytic neoplasms, with recently described application in paraffin-embedded tissues. 1, 2, 6, 7, 40, 45, 46 We found that neither of these markers was useful to distinguish myeloid LC and BPDCN in this scenario because neither entity expressed this marker to any significant extent (0% of BPDCN and 30% of myeloid LC cases). In addition, the interpretation of these markers in histologic skin sections is difficult owing to significant numbers of background, presumably nonneoplastic, dendritic cells.
An issue that did not arise in our cohort was the presence of extranodal aggregates of plasmacytoid dendritic cells in patients with myeloid leukemia. 12, [47] [48] [49] [50] It may be difficult or impossible to distinguish between this rare occurrence and extranodal accumulations of leukemic blasts in myeloid LC,
